Reading Time: 2 minutes

Vancouver, British Columbia–(Newsfile Corp. – July 16, 2020) –  BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark”) announced today that the Company has been granted a Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name “BioMark”. The term “BioMark” was selected by the company in reference to their Biomarker Testing capabilities in the fields of cancer treatment and anti-cancer preparations.

Biomarker testing is comprised of a group of tests that looks for specific molecular signs (or signatures) related to cancer so that doctors can plan the best cancer treatment care. In addition, the trademark can also be used for claiming preparation of anti-cancer properties.

“We believe that this trademark significantly enhances our brand while clearly communicating our mission and proficiency in leveraging novel biomarker testing methods for cancer treatment and development of anti-cancer preparation,” said Rashid Bux, Chief Executive Officer of BioMark Diagnostics Inc. “Going forward, this trademark will provide us with an additional layer of name recognition with investors, potential bio-technology partners and members of the scientific community. This is an opportune time to receive the trademark as we strive to accelerate commercialization of our assays and to establish ourselves as a market leader in the rapidly growing cancer medical testing, treatment and anti-cancer preparation sector.”

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. The company is also developing a rapid coronavirus detection platform under Bio-Stream Diagnostics Inc.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.

For further information on BioMark, please Contact:

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: [email protected]

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved the content of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/59870

Powered by WPeMatico